These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25819721)

  • 1. Prostate cancer risk calculators using ERSPC-derived data underestimate the risk if the WHO IRP 96/670 standard is used in prostate-specific antigen analysis.
    Tormey WP
    Eur Urol; 2015 Sep; 68(3):541-2. PubMed ID: 25819721
    [No Abstract]   [Full Text] [Related]  

  • 2. What is a "Diagnostic Test Reference Range" Good for?
    Habibzadeh P; Yadollahie M; Habibzadeh F
    Eur Urol; 2017 Nov; 72(5):859-860. PubMed ID: 28558944
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: Rescreening policies and risk calculators.
    Roobol MJ
    Nat Rev Urol; 2014 Aug; 11(8):429-30. PubMed ID: 24980199
    [No Abstract]   [Full Text] [Related]  

  • 4. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Taneja SS
    J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate-specific antigen screening for prostate cancer in males older than 75 years.
    Luján M; Páez Á
    Med Clin (Barc); 2019 Mar; 152(6):237-240. PubMed ID: 30220470
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
    McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
    Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
    [No Abstract]   [Full Text] [Related]  

  • 8. The dilemmas of prostate cancer screening.
    Hugosson J; Carlsson SV
    Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pendulum swings back: Screening for prostate cancer in 2018.
    Thompson IM
    Cancer; 2018 Jul; 124(13):2690-2692. PubMed ID: 29786846
    [No Abstract]   [Full Text] [Related]  

  • 13. First, do no harm.
    Pimlott N
    Can Fam Physician; 2012 Sep; 58(9):915. PubMed ID: 22972717
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

  • 15. The Era of Prostate-specific Antigen-based Personalized Prostate Cancer Screening Has Only Just Begun.
    Schlomm T
    Eur Urol; 2015 Aug; 68(2):214-5. PubMed ID: 25680240
    [No Abstract]   [Full Text] [Related]  

  • 16. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?
    Roobol MJ
    Eur Urol; 2015 Sep; 68(3):363-4. PubMed ID: 25769985
    [No Abstract]   [Full Text] [Related]  

  • 17. Doing it right: how, not whether, to perform prostate-specific antigen screening.
    Martin NE
    Eur Urol; 2015 Sep; 68(3):361-2. PubMed ID: 25794459
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk-based prostate cancer screening: who and how?
    Glass AS; Cary KC; Cooperberg MR
    Curr Urol Rep; 2013 Jun; 14(3):192-8. PubMed ID: 23532499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward a smarter prostate cancer screening program.
    Sjoberg DD
    Eur Urol; 2015 Oct; 68(4):598-9. PubMed ID: 24836056
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer risk assessment tools in an unscreened population.
    Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
    World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.